Hancock Jaffe Changes Name To enVVeno, Drops Cardiac Device To Focus On Venous Disease
The company will focus on developing its VenoValve system to treat chronic venous insufficiency and a second product for venous disease.
You may also be interested in...
The new public offering will fund the US pivotal trial of the company’s VenoValve device to treat chronic deep venous insufficiency in the legs.
News We’re Watching: Philips And Walgreens Settlements, ReCor Readies For Takeoff, Farapulse Trial Results
This week, Philips announced a legal settlement on recalled CPAPs and BiPAPs; the FDA released emergency preparation recommendations; ReCor prepared to bring Paradise RDN to the US market; and Abbott released the results of a trial comparing optical coherence tomography (OCT) to angiography for guidance during cardiac surgery.
This week, Medtronic presented data from two new real-world trials confirming that ICDs save lives; a restraining order was issued against EOFlow in Insulet’s intellectual property case; and Polarean’s MRI gas XENOVIEW received a new Medicare reimbursement code.